Unusual cause of dyspnea in patient with Myelofibrosis: The Ruxolitinib lung.
Mycobacterium avium
Myelofibrosis
Pulmonary alveolar proteinosis
Ruxolitinib
Journal
Respiratory medicine case reports
ISSN: 2213-0071
Titre abrégé: Respir Med Case Rep
Pays: England
ID NLM: 101604463
Informations de publication
Date de publication:
2024
2024
Historique:
received:
01
03
2024
accepted:
27
03
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
Although pulmonary complications are frequent in patients suffering from hematological diseases, secondary pulmonary alveolar proteinosis is a very rare complication of myelofibrosis. We describe the case of a 65-year-old male patient treated by Ruxolitinib for myelofibrosis who developed a secondary pulmonary alveolar proteinosis complicated by a
Identifiants
pubmed: 39206099
doi: 10.1016/j.rmcr.2024.102090
pii: S2213-0071(24)00113-8
pmc: PMC11350458
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
102090Informations de copyright
© 2024 The Authors. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: A. El Kik, M. Vander Kuylen, B. Bailly and J. Fallas have no conflict of interests to report. B. Bondue discloses no conflict of interest in relationship with the present work. However, he discloses consultancy fees from Boehringer Ingelheim Medtronic and Lys Medical and research funding from the Fonds Erasme and Boehringer Ingelheim.